Pay in 4 interest-free payments of $6.37 Learn more
Ships within 48 hours · Estimated delivery Aug 23 - Aug 28
Accordingly, the once-daily (50 mg) oral formulation of semaglutide has in a recent phase-3 trial for obesity demonstrated equivalent placebo-corrected weight loss efficacy ( OASIS1 trial ) as previously reported for injectable semaglutide (2.4 mg, STEP1 phase-3 trial )
Drawbacks: Semaglutide is less effective than other options
Meanwhile, research on synergistic effects with other anti-aging substances will be further deepened, providing important support for establishing multi-target, multi-pathway anti-aging intervention systems
THE MOST IMPORTANT THINGS AT A GLANCE
Although Sanofi's management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements
